ALX Oncology Q3 2020 Earnings Report
Key Takeaways
ALX Oncology reported its third quarter 2020 financial results, highlighting progress in advancing ALX148 in clinical trials, securing a clinical trial collaboration with Merck, and presenting encouraging data from the ASPEN-01 Phase 1b Study.
Continued to make substantial progress in advancing ALX148 in clinical trials.
Secured a clinical trial collaboration with Merck to study the combination of ALX148 with KEYTRUDA® in the setting of first line, metastatic or unresectable, recurrent head and neck squamous cell cancer.
The first patient has been dosed in the Phase 1/2 ASPEN-02 study evaluating the combination of ALX148 with azacitidine for the treatment of patients with higher-risk myelodysplastic syndromes.
Presented further encouraging data for ALX148 from the ASPEN-01 Phase 1b Study at the 35th Annual SITC meeting, including a 64% ORR in advanced gastric cancer patients treated with ALX148 in combination with trastuzumab and the current chemotherapeutic standard of care.